Amicus price target raised to $16 from $14 at BTIG

BTIG analyst Yun Zhong raised the firm’s price target on Amicus to $16 from $14 and keeps a Buy rating on the shares. The analyst contends that the company’s expectations for "multiple approvals and launched in 2023 for AT-GAA" that Amicus included in last week’s corporate update could include the U.S. as well given the management’s confidence that the manufacturing facility inspection by the FDA should be a 2023 event. Zhong adds that the removal of the travel restrictions and quarantine requirements in China should also lower the hurdles for the FDA to plan an on-site inspection.